COPYRIGHT © DIGITAL JOURNAL INC. Sitemaps: XML / News. Digital Journal is not responsible for the content of external sites. Read more about our external linking
Las Vega (Nevada), United States //— DelveInsight’s “Metastatic Renal Cell Carcinoma (mRCC) Pipeline Insight, 2023” report by DelveInsight outlines a comprehensive assessment of the present clinical/non-clinical development activities and growth prospects across the Metastatic Renal Cell Carcinoma Market.
The Metastatic Renal Cell Carcinoma Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.
As per DelveInsight’s assessment, globally, about 40+ key pharma and biotech companies are working on 50+ drugs in the Metastatic Renal Cell Carcinoma therapeutics landscape based on different Routes of Administration (RoA), Mechanism of Action (MoA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.
Metastatic Renal Cell Carcinoma (mRCC) Pipeline Analysis
The report provides insights into:
– The report provides detailed insights about emerging therapies for the treatment of Metastatic Renal Cell Carcinoma and the aggregate therapies developed by major pharma companies.
– It accesses the different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Metastatic Renal Cell Carcinoma Treatment.
– It outlines the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
– The report evaluates the drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
– It navigates the major collaborations (company-company collaborations and company-academia collaborations), licensing agreements, financing details, data presentation by the pharma giants, and regulatory approval in the Metastatic Renal Cell Carcinoma market.
The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Delveinsight’s Report Covers Emerging Products Under Different Phases of Clinical Development Like –
– Late-stage products (Phase III)
– Mid-stage products (Phase II)
– Early-stage products (Phase I/II and Phase I)
– Pre-clinical and Discovery stage candidates
– Discontinued & Inactive candidates
Metastatic Renal Cell Carcinoma (mRCC) Therapeutics Landscape
There are approx. 40+ key companies developing therapies for Metastatic Renal Cell Carcinoma. Currently, Genentech is leading the therapeutics market with its Metastatic Renal Cell Carcinoma drug candidates in the most advanced stage of clinical development.
Some of the key companies in the Metastatic Renal Cell Carcinoma (mRCC) Therapeutics Market include:
AstraZeneca, Genentech, Sumitomo Dainippon Pharma, Allogene Therapeutics, Nektar Therapeutics, Eli Lilly and Company, Xynomic Pharmaceuticals, AnewPharma, HUTCHMED, MedImmune, Incyte Corporation, NiKang Therapeutics, OncoC4, Inc., Nanobiotix, Aravive, Mirati Therapeutics Inc., BeiGene, Shanghai PerHum Therapeutics Co., Ltd., Akeso Biopharma, Novartis Pharmaceuticals, Vaccibody, SillaJen, Inc., Chongqing Precision Biotech Co., Ltd, Infinity Pharmaceuticals, Inc., SOTIO Biotech AG, Pfizer, Peloton Therapeutics, Inc., NeoTX Therapeutics Ltd., and many others.
Metastatic Renal Cell Carcinoma (mRCC) Therapies covered in the report include:
– Olaparib: AstraZeneca
– Atezolizumab: Genentech
– TP-1454: Sumitomo Dainippon Pharma
And many more
Explore More About the Emerging Drugs and Key Companies: Metastatic Renal Cell Carcinoma Pipeline Development Activities
Table of Content (TOC)
1. Report Introduction
2. Executive Summary
3. Metastatic Renal Cell Carcinoma Current Treatment Patterns
4. Metastatic Renal Cell Carcinoma – DelveInsight’s Analytical Perspective
5. Therapeutic Assessment
6. Metastatic Renal Cell Carcinoma Late-Stage Products (Phase-III)
7. Metastatic Renal Cell Carcinoma Mid-Stage Products (Phase-II)
8. Metastatic Renal Cell Carcinoma Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Metastatic Renal Cell Carcinoma Discontinued Products
13. Metastatic Renal Cell Carcinoma Product Profiles
14. Key Companies in the Metastatic Renal Cell Carcinoma Market
15. Key Products in the Metastatic Renal Cell Carcinoma Therapeutics Segment
16. Dormant and Discontinued Products
17. Metastatic Renal Cell Carcinoma Unmet Needs
18. Metastatic Renal Cell Carcinoma Future Perspectives
19. Metastatic Renal Cell Carcinoma Analyst Review
20. Appendix
21. Report Methodology
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Get a Detailed Assessment into the Ongoing Clinical and Regulatory Development Activities, at: Metastatic Renal Cell Carcinoma Therapeutic Outlook
Contact Info:
Shruti Thakur
Manager (Marketing and Branding)
Email: info@delveinsight.com
https://www.delveinsight.com/
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.